1432 related articles for article (PubMed ID: 25522652)
1. Current role of rituximab in systemic lupus erythematosus.
Mok CC
Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
[TBL] [Abstract][Full Text] [Related]
2. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
3. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.
Nakayamada S; Iwata S; Tanaka Y
Int J Rheum Dis; 2015 Feb; 18(2):208-18. PubMed ID: 25557245
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
Ruiz-Irastorza G; Danza A; Khamashta M
Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
Iwata S; Saito K; Hirata S; Ohkubo N; Nakayamada S; Nakano K; Hanami K; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Yoshinari H; Tanaka Y
Lupus; 2018 Apr; 27(5):802-811. PubMed ID: 29308726
[TBL] [Abstract][Full Text] [Related]
6. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
7. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapies in systemic lupus erythematosus.
Bernal CB; Zamora LD; Navarra SV
Int J Rheum Dis; 2015 Feb; 18(2):146-53. PubMed ID: 25884458
[TBL] [Abstract][Full Text] [Related]
9. [Biologics in SLE].
Karonitsch T; Aringer M
Wien Med Wochenschr; 2015 Jan; 165(1-2):40-5. PubMed ID: 25411010
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
[TBL] [Abstract][Full Text] [Related]
11. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
12. Update on B-cell targeted therapies for systemic lupus erythematosus.
Mok CC
Expert Opin Biol Ther; 2014 Jun; 14(6):773-88. PubMed ID: 24588110
[TBL] [Abstract][Full Text] [Related]
13. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
14. Biologics in SLE: the current status.
Rajadhyaksha AG; Mehra S; Nadkar MY
J Assoc Physicians India; 2013 Apr; 61(4):262-7. PubMed ID: 24482965
[TBL] [Abstract][Full Text] [Related]
15. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in systemic lupus erythematosus and lupus nephritis.
Beckwith H; Lightstone L
Nephron Clin Pract; 2014; 128(3-4):250-4. PubMed ID: 25471633
[TBL] [Abstract][Full Text] [Related]
17. Pediatric systemic lupus erythematosus in Thammasat University Hospital.
Pusongchai T; Jungthirapanich J; Khositseth S
J Med Assoc Thai; 2010 Dec; 93 Suppl 7():S283-93. PubMed ID: 21294427
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.
Tanaka Y; Takeuchi T; Miyasaka N; Sumida T; Mimori T; Koike T; Endo K; Mashino N; Yamamoto K
Mod Rheumatol; 2016; 26(1):80-6. PubMed ID: 26054418
[TBL] [Abstract][Full Text] [Related]
19. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
20. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis.
Marks SD; Tullus K
Acta Paediatr; 2010 Jul; 99(7):967-74. PubMed ID: 20222881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
